SEC Form 4 · accession 0001209191-16-156108
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald Rogers Reynolds
Director
Period of report
Dec 16, 2016
Accepted (ET)
Dec 20, 2016 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 par value per share | Dec 16, 2016 | P | 12,700 | $0.34 | A | 12,700 | D | |
| Common Stock, $.01 par value per share | Dec 16, 2016 | P | 7,350 | $0.35 | A | 20,050 | D | |
| Common Stock, $.01 par value per share | Dec 16, 2016 | P | 9,950 | $0.355 | A | 30,000 | D |
Table II — derivative securities
No Table II lines on this filing.